Olufemi Aoko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Olufemi Aoko has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Danny Cheriyan
Department of Gastroenterology, Beaumont Hospital, D09 V2N0 Dublin, Ireland
2 shared publications D. Cheriyan
Beaumont Hospital
1 shared publication- Fiona Boland
Data Science Centre, School of Population Health RCSI University of Medicine and Health Sciences Dublin Ireland
1 shared publication G. Harewood
Beaumont Hospital
1 shared publicationJ. Ryan
Beaumont Hospital
1 shared publication- John D. Ryan
Translational Gastroenterology Unit, University of Oxford, Oxford, UK
1 shared publication
Latest Publications
- Open Access
- 16 October 2025
- Published by MDPI AG in Gastroenterology Insights
- Vol. 16 (4) , 38
Outcomes of EUS-Guided Gallbladder Drainage: A Case Series from a Tertiary Referral Center in Ireland
Background/Objectives: Cholecystectomy remains the gold-standard treatment for acute cholecystitis. However, in patients deemed unfit for surgery, alternative gallbladder drainage techniques are required. These include percutaneous gallbladder drainage (PT-GBD), endoscopic transpapillary gallbladder drainage (ET-GBD), and the more recently adopted endoscopic ultrasound-guided gallbladder drainage (EUS-GBD). EUS-GBD has emerged as a promising minimally invasive option, offering high technical and clinical success with fewer complications and need for reinterventions. The objective of this study was to evaluate the clinical outcomes of EUS-GBD in high-risk surgical patients with acute cholecystitis. Methods: We conducted a single-center retrospective study evaluating outcomes of EUS-GBD in a tertiary referral center in Ireland. Data from ten high-risk patients with acute cholecystitis who underwent EUS-GBD using a 15 mm × 10 mm HOT AXIOS lumen-apposing metal stent (LAMS) between October 2017 and September 2018 were analyzed. Parameters assessed included technical and clinical success, adverse events, and 1-year mortality. Results: The mean age of patients was 79.5 years (range 65–95). Technical success of stent placement was achieved in all patients with no immediate complications. A trans-gastric approach was used in 7 patients while a trans-duodenal route was employed in the remaining 3. 1–year mortality following EUS-GBD was 20%. Stents were not removed in any patient in this series. No patient experienced stent-related adverse events, re-occurrence of cholecystitis, or the need for re-intervention. Conclusions: EUS-GBD has very high technical and clinical success rates, with low risk of complications and need for re-intervention in comparison to other options of GB decompression. It is, however, not widely available, and it requires a skilled endoscopist with experience in interventional EUS.
- 16 October 2025
- Published by MDPI AG in Gastroenterology Insights
- Vol. 16 (4) , 38
Open AccessOutcomes of EUS-Guided Gallbladder Drainage: A Case Series from a Tertiary Referral Center in Ireland
Background/Objectives: Cholecystectomy remains the gold-standard treatment for acute cholecystitis. However, in patients deemed unfit for surgery, alternative gallbladder drainage techniques are required. These include percutaneous gallbladder drainage (PT-GBD), endoscopic transpapillary gallbladder drainage (ET-GBD), and the more recently adopted endoscopic ultrasound-guided gallbladder drainage (EUS-GBD). EUS-GBD has emerged as a promising minimally invasive option, offering high technical and clinical success with fewer complications and need for reinterventions. The objective of this study was to evaluate the clinical outcomes of EUS-GBD in high-risk surgical patients with acute cholecystitis. Methods: We conducted a single-center retrospective study evaluating outcomes of EUS-GBD in a tertiary referral center in Ireland. Data from ten high-risk patients with acute cholecystitis who underwent EUS-GBD using a 15 mm × 10 mm HOT AXIOS lumen-apposing metal stent (LAMS) between October 2017 and September 2018 were analyzed. Parameters assessed included technical and clinical success, adverse events, and 1-year mortality. Results: The mean age of patients was 79.5 years (range 65–95). Technical success of stent placement was achieved in all patients with no immediate complications. A trans-gastric approach was used in 7 patients while a trans-duodenal route was employed in the remaining 3. 1–year mortality following EUS-GBD was 20%. Stents were not removed in any patient in this series. No patient experienced stent-related adverse events, re-occurrence of cholecystitis, or the need for re-intervention. Conclusions: EUS-GBD has very high technical and clinical success rates, with low risk of complications and need for re-intervention in comparison to other options of GB decompression. It is, however, not widely available, and it requires a skilled endoscopist with experience in interventional EUS.
- Open Access
- 20 November 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (1) , 8-22
Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity
Summary: Background: Non‐alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease affecting approximately 25% of adults in the western world. Intragastric balloon (IGB) is an endoscopic bariatric therapy ‐a therapeutic endoscopic tool that has shown promise in inducing weight loss. Its role in the treatment of NAFLD is yet to be established.Aim: To evaluate the effect of IGB as a treatment option in NAFLD.Methods: We searched MEDLINE (PubMed) and EMBASE from inception to September 2022. We included studies evaluating the impact of IGB on obesity with the assessment of one or more liver‐related outcomes and studies primarily evaluating the impact of IGB on NAFLD. We included comparative and non‐comparative studies; primary outcomes were liver‐related NAFLD surrogates.Results: We included 19 studies with 911 patients. IGB demonstrated an effect on NAFLD parameters including NAFLD activity score (NAS): mean difference (MD): −3.0 [95% CI: −2.41 to −3.59], ALT: MD: −10.40 U/L [95% CI: −7.31 to −13.49], liver volume: MD ‐397.9 [95% CI: −212.78 to 1008.58] and liver steatosis: MD: −37.76 dB/m [95% CI: −21.59 to −53.92]. There were significant reductions in non‐liver‐related outcomes of body weight, BMI, glycated haemoglobin and HOMA‐IR.Conclusion: Intragastric balloons may play an important role in addressing the treatment gap in NAFLD management.
- 20 November 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (1) , 8-22
Open AccessMeta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity
Summary: Background: Non‐alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease affecting approximately 25% of adults in the western world. Intragastric balloon (IGB) is an endoscopic bariatric therapy ‐a therapeutic endoscopic tool that has shown promise in inducing weight loss. Its role in the treatment of NAFLD is yet to be established.Aim: To evaluate the effect of IGB as a treatment option in NAFLD.Methods: We searched MEDLINE (PubMed) and EMBASE from inception to September 2022. We included studies evaluating the impact of IGB on obesity with the assessment of one or more liver‐related outcomes and studies primarily evaluating the impact of IGB on NAFLD. We included comparative and non‐comparative studies; primary outcomes were liver‐related NAFLD surrogates.Results: We included 19 studies with 911 patients. IGB demonstrated an effect on NAFLD parameters including NAFLD activity score (NAS): mean difference (MD): −3.0 [95% CI: −2.41 to −3.59], ALT: MD: −10.40 U/L [95% CI: −7.31 to −13.49], liver volume: MD ‐397.9 [95% CI: −212.78 to 1008.58] and liver steatosis: MD: −37.76 dB/m [95% CI: −21.59 to −53.92]. There were significant reductions in non‐liver‐related outcomes of body weight, BMI, glycated haemoglobin and HOMA‐IR.Conclusion: Intragastric balloons may play an important role in addressing the treatment gap in NAFLD management.
- Open Access
- 1 August 2022
- Published by Springer Nature in Research Square
Impact of Covid-19 Pandemic on Diagnosis of Oesophageal and Gastric Cancers – A Single Centre Study
BACKGROUND Due to a huge focus of healthcare resources on acute COVID-19 care during the early phase of the pandemic, endoscopy activity worldwide was significantly reduced. This subsequently led to a reduction in the number of Oesophageal and Gastric cancers diagnosed during this period, resulting in delayed diagnosis. AIM To measure the impact of COVID-19 pandemic on the diagnosis of Oesophageal and Gastric cancers in a single tertiary referral centre. METHODS This was a retrospective study. Patients were divided into three groups based on the period of diagnosis. Period A represented October 2019 – March 2020, B represented April 2020-June 2020, and C represented July 2020-October 2020. Patients were then further subdivided based on the stage of the cancer at diagnosis. RESULTS A total of 153 patients diagnosed between October 2019 and October 2020 were included. The mean age was 69.4. During period B, which correlates with the early phase of the pandemic, and reduced endoscopy activity, there was a reduction in the number of cancers diagnosed. 66 patients (43.1%) were diagnosed in Period A, 25 (16.3%) in Period B and 62 (40.5%) in Period C. In respect to Period B, in comparison to the same period in 2019, 40 patients were diagnosed. There was also an increase in the number of cancers diagnosed at an advanced stage in Period C, correlating with the recovery/decelerating phase of the first wave of the pandemic. CONCLUSION This study highlights the risk associated with delayed diagnosis of Upper GI Cancers due to the pandemic.
- 1 August 2022
- Published by Springer Nature in Research Square
Open AccessImpact of Covid-19 Pandemic on Diagnosis of Oesophageal and Gastric Cancers – A Single Centre Study
BACKGROUND Due to a huge focus of healthcare resources on acute COVID-19 care during the early phase of the pandemic, endoscopy activity worldwide was significantly reduced. This subsequently led to a reduction in the number of Oesophageal and Gastric cancers diagnosed during this period, resulting in delayed diagnosis. AIM To measure the impact of COVID-19 pandemic on the diagnosis of Oesophageal and Gastric cancers in a single tertiary referral centre. METHODS This was a retrospective study. Patients were divided into three groups based on the period of diagnosis. Period A represented October 2019 – March 2020, B represented April 2020-June 2020, and C represented July 2020-October 2020. Patients were then further subdivided based on the stage of the cancer at diagnosis. RESULTS A total of 153 patients diagnosed between October 2019 and October 2020 were included. The mean age was 69.4. During period B, which correlates with the early phase of the pandemic, and reduced endoscopy activity, there was a reduction in the number of cancers diagnosed. 66 patients (43.1%) were diagnosed in Period A, 25 (16.3%) in Period B and 62 (40.5%) in Period C. In respect to Period B, in comparison to the same period in 2019, 40 patients were diagnosed. There was also an increase in the number of cancers diagnosed at an advanced stage in Period C, correlating with the recovery/decelerating phase of the first wave of the pandemic. CONCLUSION This study highlights the risk associated with delayed diagnosis of Upper GI Cancers due to the pandemic.